Flagship explainer

How Sarepta Therapeutics, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$1.9B · 100%Cost of revenue$25.5M · 1%Gross profit$1.8B · 99%Operating income−$700M · −38%Income before tax−$702M · −38%Income tax$11.2M · 1%Net income−$713M · −38%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$1.9B100%
Cost of revenue$25.5M1%
$1.8B99%
−$700M−38%
Income before tax−$702M−38%
Income tax$11.2M1%
−$713M−38%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

View the full Sarepta Therapeutics, Inc. analysis at Buy Like Buffett